— Know what they know.
/
Not Investment Advice

BMY

NYSE · USD
Bristol-Myers Squibb Company
Healthcare · Drug Manufacturers - General
CEO Christopher Boerner Employees 32,500 R&D / revenue 19.9%
Last price
$59.75−1.35%last session
Market cap
$122.1B
P/E (TTM)
13.2x
From 52w high
−13.0%
From 52w low
+40.5%
1-year return
+43.8%
RSI 14 · vs SMA200
45.5 · +2.2%
IS score
67.7/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

BMY   SPY   XLV (sector ETF) · weekly closes
100120140160Jan 26Apr 26Jul 26Oct 26BMY 144XLV 124SPY 116

Score DNA

Each bar is a 0-100 score within the scored universe
89
Profitability
63
Growth
67
Value
87
Momentum
65
Risk (safety)
80
Quality
53
Balance sheet
71
Earnings quality

Flags

Strengths
✓ Piotroski 8+✓ FCF yield 5%+
Warnings
▲ Share count rising
Observations
Moat model: Narrow, Efficient ScalePiotroski 8 / 9Altman Z 2.6Beta 0.232 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
0
2 open-market sales, $437,248
No Form 144 notices in 12 months
CONGSTOCK Act · 180 days
Congressional purchases
0
No disclosed purchases
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
−11
177 new holders, 159 closed
2,534 filers hold 85.4% · 1,005 added, 1,006 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+419
1,731 funds adding shares
1,312 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
39.3%
20-day avg 44.2%, 50-day avg 48.6%
Latest 4.9 pp under its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$48.2B
Revenue growth YoY−0.2%
Gross margin67.6%
Operating income$12.7B
Operating margin26.3%
Net income$7.1B
Net margin14.6%
EPS (diluted)$3.45
Cash flow
Operating cash flow$14.2B
Capital expenditure$1.3B
Free cash flow$12.8B
FCF conversion (FCF / OCF)90.7%
Stock-based compensation$553.0M
FCF less SBC$12.3B
Buybacks$0
Dividends$5.0B
Balance sheet & returns
Cash & short-term investments$10.7B
Total debt$45.1B
Net debt$34.4B
Shareholders' equity$18.5B
Goodwill & intangibles$40.9B
Debt / equity1.93
ROE (TTM)46.8%
ROIC (TTM)15.4%
Operating margin by fiscal year
16.6%FY202120.2%FY202218.8%FY202318.5%FY202426.3%FY2025
Revenue $46.4B (FY2021) to $48.2B (FY2025), a 1.0% CAGR.

Valuation

P/E (TTM)13.2x
EV / EBITDA9.3x
Price / sales2.48x
Price / FCF10.7x
FCF yield9.37%
Buyback yield0.00%
SBC / revenue1.1%
Price / book5.47x
Forward P/E FY20269.5x
Forward P/E FY20279.0x
Forward P/E FY202811.0x
Forward multiples divide today's price by Street EPS estimates. Street mean target $65.54 across 13 analysts last quarter is theirs, not ours.

BMY vs industry median

40 companies in Drug Manufacturers - General
Gross margin 70.2% 72.4% Operating margin 28.1% 20.1% Net margin 18.9% 12.7% ROIC 15.4% 16.2%
BMY (TTM)Industry median Asset turnover 0.56 vs industry 0.54 · financial leverage 3.93

Earnings delivery

Next report 2026-10-29 · consensus EPS $1.09
100%
beat rate, 12 of 12 quarters
+13.6%
median EPS surprise
12
longest beat streak
+14+12+0+28+21+14+21+34+7+2+11+27
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-10-26 to 2026-07-30. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
BMY Bristol-Myers Squibb Company $122.1B13.2x46.8%18.9%−0.2% +43.8%
PFE Pfizer Inc. $168.6B39.1x5.0%-1.6%−0.2% +24.2%
GILD Gilead Sciences, Inc. $193.7Bn/m-20.6%—+5.5% +33.4%
AMGN Amgen Inc. $233.8B26.7x91.5%23.6%+9.2% +50.3%
AZN AstraZeneca PLC $256.5B24.7x22.0%16.3%+8.6% −1.5%
NVS Novartis AG $286.3B22.9x30.6%22.7%+0.8% —
MRK Merck & Co., Inc. $360.1B115.8x7.0%-8.0%+4.5% —
BIIB Biogen Inc. $34.4B41.0x4.6%3.6%−0.5% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

No 8-K filings on file.

Context

Shares outstanding2,042,710,000
Free float99.8%
Institutional ownership85.4%
Beta0.23
Dividend yield4.22%
Last dividend$0.63 on 2026-10-02
50 / 200-day average$63.59 / $59.61
Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Narrow).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where BMY sits among 12 scored companies in Drug Manufacturers - General (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureBMYIndustry medianIndustry percentileSector median
P/E (TTM) 13.2x 29.3x
0th		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) 2.14 1.23
80th		 1.28
Price / sales 2.5x 5.3x
9th		 3.7x
Price / book 5.5x 6.9x
40th		 3.6x
Price / tangible book —
Price / free cash flow 10.7x 20.3x
9th		 21.2x
Price / operating cash flow 9.5x 16.8x
9th		 17.1x
Enterprise value $154.1B $280.5B
18th		 $2.5B
EV / sales 3.1x 6.0x
9th		 3.8x
EV / EBITDA 9.6x 18.0x
9th		 16.2x
EV / EBIT 11.8x 24.8x
10th		 23.0x
EV / free cash flow 13.5x 23.7x
0th		 24.6x
Earnings yield 7.6% 3.0%
100th		 -0.3%
FCF yield 9.4% 5.0%
91st		 1.7%
Operating cash flow yield 10.5% 6.0%
91st		 2.9%
Graham number (per share) $33.33 $63.36
33rd		 $26.70

Profitability (TTM)

MeasureBMYIndustry medianIndustry percentileSector median
Gross margin 70.2% 72.1%
27th		 65.1%
EBITDA margin 32.8% 32.8%
45th		 6.6%
Operating margin 25.3% 25.2%
55th		 3.5%
EBIT margin 26.6% 22.0%
73rd		 2.4%
Net margin 18.9% 13.4%
64th		 0.3%
NOPAT margin 19.7% 20.5%
45th		 2.7%
FCF margin 23.3% 24.7%
36th		 4.3%
Operating cash flow margin 26.0% 29.5%
36th		 7.1%
R&D / revenue 21.8% 20.0%
82nd		 12.4%
SG&A / revenue 15.1% 22.0%
0th		 37.9%
Stock comp / revenue 1.1% 1.1%
55th		 4.5%
Effective tax rate 22.1% 19.2%
73rd		 21.0%

Returns on capital

MeasureBMYIndustry medianIndustry percentileSector median
ROE (on average equity) 46.7% 24.0%
80th		 0.8%
ROA 10.2% 6.9%
73rd		 -0.3%
ROIC 17.8% 15.9%
64th		 5.5%
ROCE 19.0% 15.6%
91st		 2.3%
Return on tangible assets 14.4% 11.2%
82nd		 1.7%
Cash ROIC (OCF / invested capital) 23.5% 22.4%
73rd		 9.7%
Gross profitability (GP / assets) 39.4% 34.0%
73rd		 29.9%
ROIC, 3-yr average 5.0% 10.3%
18th		 2.6%
ROIC, 5-yr average 7.1% 14.2%
11th		 3.2%
ROE, 5-yr average 15.5% 19.6%
44th		 -4.9%
Incremental ROIC -197.0% 4.4%
27th		 17.2%

Growth

MeasureBMYIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 3.1% 5.0%
36th		 10.5%
Revenue growth (QoQ) 12.9% 8.6%
73rd		 7.2%
Revenue CAGR, 3 yr 2.9% 4.4%
27th		 10.7%
Revenue CAGR, 5 yr 2.1% 3.3%
27th		 12.1%
Gross profit CAGR, 3 yr 10.5% 5.9%
73rd		 10.6%
Operating income CAGR, 3 yr 14.3% 10.0%
60th		 11.7%
Net income growth (TTM YoY) 83.8% -6.6%
90th		 17.5%
Net income CAGR, 3 yr 5.2% 3.1%
60th		 11.3%
EPS growth (TTM YoY) 82.9% -4.3%
80th		 19.2%
EPS CAGR, 3 yr 6.2% 2.7%
60th		 14.0%
EPS CAGR, 5 yr —
FCF growth (TTM YoY) -21.5% 4.7%
0th		 18.6%
FCF CAGR, 3 yr 2.2% 11.3%
27th		 15.4%
Operating cash flow CAGR, 3 yr 2.6% 6.8%
27th		 11.9%
Book value CAGR, 3 yr -10.5% 5.2%
11th		 2.1%
Dividend CAGR, 3 yr 1.8% 1.8%
40th		 2.2%
Sustainable growth rate 21.1% 11.0%
67th		 12.2%

Margin history & stability

MeasureBMYIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 62.7% 70.1%
18th		 62.6%
Operating margin, 3-yr average 23.0% 23.5%
45th		 1.0%
Net margin, 3-yr average 5.1% 13.4%
9th		 -2.6%
FCF margin, 3-yr average 27.2% 22.0%
73rd		 3.2%
Revenue stability (0-1) 0.94 0.75
91st		 0.80
Earnings stability (0-1) 0.17 0.23
45th		 0.37
Margin stability (0-1) 0.90 0.94
9th		 0.93

Liquidity (latest quarter)

MeasureBMYIndustry medianIndustry percentileSector median
Cash & short-term investments $11.1B $7.4B
73rd		 $330.9M
Net cash (− = net debt) −$32.1B −$36.7B
55th		 $8.4M
Working capital $9.9B $4.1B
91st		 $381.1M
Current ratio 1.53 1.29
82nd		 3.02
Quick ratio 1.38 1.05
91st		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.59 0.31
100th		 1.43
Defensive interval (days) 358 days 287 days
64th		 415 days

Leverage & solvency (latest quarter)

MeasureBMYIndustry medianIndustry percentileSector median
Total debt $43.1B $49.0B
36th		 $289.1M
Debt / equity 1.93 1.29
70th		 0.45
Net debt / equity 1.44 1.12
70th		 −0.13
Debt / assets 49.2% 40.8%
64th		 24.4%
Debt / capital 65.9% 56.2%
70th		 31.1%
Debt / EBITDA 2.68 3.30
36th		 2.62
Net debt / EBITDA 1.99 2.75
36th		 1.42
Interest coverage (EBIT / interest) 9.7x 5.3x
73rd		 2.1x
Cash interest coverage 9.5x 9.8x
45th		 3.6x
Debt payback (years of OCF) 3.4 yrs 2.8 yrs
64th		 2.7 yrs
Liabilities / assets 74.5% 71.1%
55th		 49.8%
IS credit model rating BBB+ — —
Implied credit spread (bps) 225 250
45th		 225

Efficiency

MeasureBMYIndustry medianIndustry percentileSector median
Asset turnover 0.54 0.49
82nd		 0.56
Fixed asset turnover 6.31 4.31
91st		 4.87
Inventory turnover 5.4 2.1
100th		 2.7
Receivables turnover 4.9 4.9
36th		 6.4
Days sales outstanding 75 days 74 days
64th		 57 days
Days inventory outstanding 68 days 172 days
0th		 136 days
Days payables outstanding 119 days 116 days
55th		 59 days
Cash conversion cycle (days) 24 days 126 days
27th		 70 days
Capex / revenue 2.7% 4.6%
20th		 2.6%
Capex / depreciation 0.45 0.49
30th		 0.55
Operating expense ratio 40.3% 40.9%
45th		 56.5%

Cash flow & earnings quality

MeasureBMYIndustry medianIndustry percentileSector median
Operating cash flow / net income 1.38 1.44
30th		 1.61
FCF / net income 1.23 1.24
40th		 1.36
FCF / operating cash flow 89.5% 81.5%
80th		 81.2%
Capex / operating cash flow 10.5% 18.5%
20th		 18.8%
Accruals ratio -3.8% -4.3%
73rd		 -5.4%
Sloan accruals ratio 1.3% -2.6%
82nd		 -1.3%
Earnings quality score (0-1) 1.00 1.00
30th		 0.75

Dividends & buybacks

MeasureBMYIndustry medianIndustry percentileSector median
Dividend yield 4.2% 2.2%
91st		 0.0%
Dividend per share (TTM) $2.52 $3.33
27th		 $0.00
Payout ratio (dividends / net income) 54.9% 60.0%
40th		 0.0%
Dividends / FCF 44.5% 50.8%
36th		 0.0%
Dividend growth (YoY) 2.3% 5.0%
20th		 4.5%
Buyback yield 0.1% 0.1%
36th		 0.0%
Shareholder yield (dividends + buybacks) 4.3% 2.5%
82nd		 0.0%
Share count change (YoY) 0.5% -0.1%
64th		 2.0%
Buybacks, last 5 years $196.0M $3.6B
27th		 $0

Scores & forensic checks

MeasureBMYIndustry medianIndustry percentileSector median
IS score 68 64
82nd		 46
IS profitability 89 67
82nd		 22
IS growth 63 40
64th		 60
IS value 67 42
100th		 39
IS momentum 87 67
64th		 67
IS risk (safety) 65 72
36th		 80
IS quality 80 72
73rd		 49
IS balance sheet 53 49
64th		 55
IS earnings quality 71 68
73rd		 56
IS cash flow 62 66
18th		 41
Piotroski F-score (0-9) 8 7
73rd		 5
Altman Z-score 2.6 3.0
36th		 3.2
Beneish M-score −2.98 −2.72
9th		 −2.62
Ohlson O-score −7.96 −8.11
55th		 −7.16
IS credit score 63 60
55th		 62

Per share

MeasureBMYIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $4.53 $5.07
45th		 −$0.03
Book value per share $10.90 $19.22
27th		 $7.10
Tangible book per share −$8.23 −$8.38
55th		 $1.91
Revenue per share $24.02 $32.71
18th		 $9.38
FCF per share $5.59 $7.97
18th		 $0.46
Operating cash flow per share $6.24 $9.66
18th		 $0.93
Cash per share $5.40 $4.10
64th		 $3.51

Size (TTM)

MeasureBMYIndustry medianIndustry percentileSector median
Market cap $122.1B $245.2B
18th		 $2.4B
Revenue $49.2B $58.5B
36th		 $770.2M
EBITDA $16.1B $16.9B
45th		 $56.1M
Net income $9.3B $7.5B
64th		 −$3.3M
Free cash flow $11.4B $12.3B
45th		 $41.2M
Total assets $87.6B $118.9B
27th		 $1.3B
Shareholders' equity $22.3B $28.1B
45th		 $568.4M
Employees 32,500 53,500
36th		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-10-02Gallman Cari
EVP, General Counsel
 Option exercise 4,559——18,208
2026-10-02Gallman Cari
EVP, General Counsel
 Tax withholding 2,332$61.15$142,60215,876
2026-10-02Gallman Cari
EVP, General Counsel
 Option exercise 4,559——0
2026-09-30Yale Phyllis R
Director
 Award / grant 561——45,980
2026-09-30Samuels Theodore R. Ii
Director
 Award / grant 821——71,859
2026-09-30Rice Derica W
Director
 Award / grant 621——42,085
2026-09-30Mcmullen Michael R.
Director
 Award / grant 561——17,051
2026-09-30Arduini Peter J
Director
 Award / grant 561——74,077
2026-09-09Massacesi Cristian
EVP,Chief Med Offr,Head of Dev
 Open-market sale 6,249$64.57$403,49818,748
2026-09-01Short Bartie Wendy
EVP, Corporate Affairs
 Option exercise 1,236$66.92$82,71313,317
2026-09-01Short Bartie Wendy
EVP, Corporate Affairs
 Tax withholding 633$66.92$42,36012,684
2026-09-01Short Bartie Wendy
EVP, Corporate Affairs
 Option exercise 1,236——0

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarAprMayJunAugSepOct

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired106,509—
Open-market saleDisposed26,749$437,248
Option exerciseDisposed787,901$1.1M
Option exerciseAcquired787,901$1.2M
OtherDisposed1203—
Tax withholdingDisposed634,158$2.2M
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

FiledFilerShares proposedEst. proceeds
None on file.
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 14 trades (4 purchases) · Senate 0 (0 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-05-07Mike KellyHouseSale$15,001 - $50,0002026-06-12
2026-05-07Mike KellyHouseSale (Full)$15,001 - $50,0002026-06-12
2026-05-06Mike KellyHouseSale (Full)$15,001 - $50,0002026-06-12
2026-01-29Ro KhannaHouseSale$15,001 - $50,0002026-02-10
2025-04-15Tommy TubervilleSenateSale$1,001 - $15,0002026-08-05
2025-04-15Thomas Hawley TubervilleSenateSale$1,001 - $15,0002026-08-05
2025-04-15Tommy TubervilleSenateSale$1,001 - $15,0002025-05-15
2025-04-15Tommy TubervilleSenateSale (Full)$1,001 - $15,0002025-05-15
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
BlackRock, Inc.180,384,994$10.4B8.83%
VANGUARD CAPITAL MANAGEMENT LLC133,337,856$7.7B6.53%
STATE STREET CORP102,408,940$5.9B5.01%
JPMORGAN CHASE & CO64,958,301$3.8B3.18%
GEODE CAPITAL MANAGEMENT, LLC56,443,077$3.2B2.76%
VANGUARD PORTFOLIO MANAGEMENT LLC46,873,015$2.7B2.29%
NORGES BANK36,866,658$2.1B1.80%
BANK OF AMERICA CORP /DE/34,045,352$2.0B1.67%
PRICE T ROWE ASSOCIATES INC /MD/31,707,643$1.8B1.55%
AMERIPRISE FINANCIAL INC26,670,064$1.5B1.31%
PRIMECAP MANAGEMENT CO/CA/24,923,900$1.4B1.22%
Independent Franchise Partners LLP21,792,841$1.3B1.07%
Bank of New York Mellon Corp20,683,684$1.2B1.01%
DIMENSIONAL FUND ADVISORS LP19,691,951$1.1B0.96%
NORTHERN TRUST CORP18,858,883$1.1B0.92%

Institutional ownership by quarter

2023-092026-0685.4%
% of shares held by 13F filers
2023-092026-062,534
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-302,53485.4%1771,0051,006159
2026-03-312,54579.3%2711,065880148
2025-12-312,46680.4%383873959141
2025-09-302,27677.8%161835990152
2025-06-302,30580.6%1538261,035305
2025-03-312,49080.0%204957991164
2024-12-312,49678.3%377931918111
2024-09-302,26975.9%269822932134
2024-06-302,16175.2%1736921,051322
2024-03-312,34476.5%176939970174
2023-12-312,37175.9%2566711,213241
2023-09-302,39776.9%1197861,186179

Schedule 13D / 13G filers

FiledFormFiler% of classShares
None on file.
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.17%$4.0B
VTI0.17%$4.0B
VSMPX0.17%$4.0B
VTSAX0.17%$4.0B
SCHD3.03%$3.4B
VOO0.19%$3.3B

Share structure

Shares outstanding2,042,710,000
Float2,039,548,448
Free float99.8%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$46.4B$46.2B$45.0B$48.3B$48.2B
Cost of revenue$19.6B$19.7B$19.6B$20.9B$15.6B
Gross profit$26.8B$26.5B$25.4B$27.4B$32.6B
R&D$9.5B$9.4B$9.2B$9.8B$9.6B
SG&A$7.7B$7.8B$7.7B$7.9B$7.2B
Operating income$9.5B$9.3B$8.5B$9.7B$12.7B
EBITDA$20.1B$19.2B$19.4B$3.2B$14.5B
Pretax income$8.1B$7.7B$8.4B−$8.4B$9.3B
Income tax$1.1B$1.4B$400.0M$554.0M$2.3B
Net income$7.0B$6.3B$8.0B−$8.9B$7.1B
EPS, diluted$3.12$2.95$3.86$-4.41$3.45
Diluted shares2.2B2.1B2.1B2.0B2.0B

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$17.2B$9.3B$12.3B$10.9B$10.7B
Receivables$12.5B$13.9B$15.3B$14.4B$14.5B
Inventory$2.1B$2.3B$2.7B$2.6B$2.7B
Total current assets$33.3B$27.3B$31.8B$29.8B$29.4B
PP&E, net$7.0B$7.5B$8.0B$8.4B$9.1B
Goodwill & intangibles$63.3B$57.5B$48.7B$45.4B$40.9B
Total assets$109.3B$96.8B$95.2B$92.6B$90.0B
Accounts payable$2.9B$3.0B$3.3B$3.6B$3.6B
Total current liabilities$21.9B$21.9B$22.3B$23.8B$23.4B
Long-term debt$39.6B$35.1B$36.7B$47.6B$42.9B
Total liabilities$73.3B$65.7B$65.7B$76.2B$71.5B
Shareholders' equity$36.0B$31.1B$29.5B$16.4B$18.5B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$7.0B$6.3B$8.0B−$8.9B$7.1B
Depreciation & amortization$10.7B$10.3B$9.8B$9.6B$4.0B
Stock-based compensation$583.0M$457.0M$518.0M$507.0M$553.0M
Change in working capital−$1.3B−$2.2B−$1.9B$810.0M−$455.0M
Operating cash flow$16.2B$13.1B$13.9B$15.2B$14.2B
Capital expenditure−$973.0M−$1.1B−$1.2B−$1.2B−$1.3B
Free cash flow$15.2B$11.9B$12.7B$13.9B$12.8B
Investing cash flow−$538.0M−$1.1B−$2.3B−$21.4B−$4.1B
Net debt issued / repaid−$6.2B−$5.3B$456.0M$10.1B−$5.2B
Buybacks−$6.3B−$8.0B−$5.2B$0$0
Dividends paid−$4.4B−$4.6B−$4.7B−$4.9B−$5.0B

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin57.7%57.4%56.3%56.8%67.6%
Operating margin16.6%20.2%18.8%18.5%26.3%
Net margin15.1%13.7%17.8%-18.5%14.6%
FCF margin32.8%25.9%28.1%28.9%26.7%
ROE19.0%18.9%26.5%-39.1%40.5%
ROIC10.4%12.3%13.7%12.5%17.5%
ROA6.1%6.1%8.4%-9.5%7.7%
Debt / equity1.271.311.413.132.55
Interest coverage7.1x7.3x8.2xn/m7.1x
Current ratio1.521.251.431.251.26
Revenue growth+9.1%−0.5%−2.5%+7.3%−0.2%
EPS growth+178.7%−5.5%+32.5%−211.3%+178.7%
P/E at year end16.8x21.1x11.8xn/m15.4x
EV / EBITDA at year end7.2x8.6x6.4x47.4x10.0x
FCF yield at year end12.97%8.93%13.38%12.70%11.81%
Dividend payout62.9%73.2%59.1%—71.5%

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
Eliquis$10.8B$11.8B$12.2B$13.3B$14.4B
Revlimid$12.8B$10.0B$6.1B$5.8B$3.0B
Opdivo$7.5B$8.2B$9.0B$9.3B$10.0B
Orencia$3.3B$3.5B$3.6B$3.7B$3.7B
Pomalyst/Imnovid$3.3B$3.5B$3.4B$3.5B$2.7B
Yervoy$2.0B$2.1B$2.2B$2.5B$2.9B
Reblozyl$551.0M$717.0M$1.0B$1.8B$2.3B
Sprycel$2.1B$2.2B$1.9B$1.3B$493.0M
Other Growth Brands———$1.6B$1.9B
Mature Products And All Other$1.9B$1.7B———
Breyanzi$87.0M$182.0M$364.0M$747.0M$1.4B
Opdualag—$252.0M$627.0M$928.0M$1.2B
Abraxane$1.2B$811.0M$1.0B$875.0M$368.0M
Camzyos—$24.0M$231.0M$602.0M$1.1B
Other Legacy Brands———$925.0M$798.0M
Zeposia$134.0M$250.0M$434.0M$566.0M$577.0M
Abecma$164.0M$388.0M$472.0M$406.0M$427.0M
Sotyktu—$8.0M$170.0M$246.0M$291.0M
Opdivo Ovantig————$238.0M
Krazati———$126.0M$205.0M
Cobenfy———$10.0M$155.0M

Revenue by region · FY2025

UNITED STATES$33.3B · 97%
Other Region$1.1B · 3%

Street estimates by fiscal year

Next report 2026-10-29 · consensus EPS $1.09 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$49.9B$49.1B – $50.1B$6.32$5.97 – $6.65179.5x
2027$48.5B$47.4B – $49.9B$6.62$6.12 – $7.42179.0x
2028$41.0B$36.3B – $44.7B$5.41$3.84 – $6.67911.0x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-07-30$1.60$2.04+27.5%$11.7B$13.0B+10.5%
2026-04-30$1.42$1.58+11.3%$10.9B$11.5B+5.1%
2026-02-05$1.23$1.26+2.4%$12.3B$12.5B+1.8%
2025-10-30$1.52$1.63+7.2%$11.9B$12.2B+3.1%
2025-07-31$1.09$1.46+33.9%$11.4B$12.3B+7.2%
2025-04-24$1.49$1.80+20.8%$10.7B$11.2B+4.7%
2025-02-06$1.47$1.67+13.6%$11.6B$12.3B+6.7%
2024-10-31$1.49$1.80+20.8%$11.3B$11.9B+5.6%
2024-07-26$1.62$2.07+27.8%$11.5B$12.2B+5.7%
2024-04-25$-4.41$-4.40+0.2%$11.5B$11.9B+3.3%
2024-02-02$1.52$1.70+11.8%$11.2B$11.5B+2.5%
2023-10-26$1.76$2.00+13.6%$11.0B$11.0B−0.0%
2023-07-27$1.99$1.75−12.1%$11.8B$11.2B−4.9%
2023-04-27$1.98$2.05+3.5%$11.5B$11.3B−1.4%
2023-02-02$1.71$1.82+6.4%$11.2B$11.4B+2.0%
2022-10-25$1.83$1.99+8.7%$11.1B$11.2B+0.7%
2022-07-27$1.79$1.93+7.8%$11.4B$11.9B+4.1%
2022-04-29$1.92$1.96+2.1%$11.4B$11.6B+2.5%
2022-02-04$1.83$1.830.0%$12.0B$12.0B−0.5%
2021-10-27$1.91$2.00+4.7%$11.6B$11.6B−0.0%
2021-07-28$1.88$1.93+2.7%$11.6B$11.7B+0.8%
2021-04-29$1.80$1.74−3.3%$11.6B$11.1B−4.2%
2021-02-04$1.37$1.46+6.6%$10.7B$11.1B+3.7%
2020-11-05$1.49$1.63+9.4%$9.6B$10.5B+9.5%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.506-150.706-220.506-290.507-060.807-130.507-201.007-271.408-030.708-100.608-170.408-240.408-31
Week ofNotionalSharesTrades
2026-08-31$414.8M6,182,049105,500
2026-08-24$388.5M5,780,95699,929
2026-08-17$592.7M8,911,470127,335
2026-08-10$692.9M10,788,147143,517
2026-08-03$1.4B20,954,500208,489
2026-07-27$987.6M15,427,017175,893

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1539.3%
DateShort shareShort volumeTotal volume
2026-10-1539.3%1,921,0004,892,990
2026-10-1444.0%2,181,0414,959,274
2026-10-1342.8%2,183,8615,097,821
2026-10-1252.1%4,192,4538,041,637
2026-10-0929.4%1,004,5113,418,395
2026-10-0828.9%1,035,9113,578,503
2026-10-0746.2%2,051,0054,437,535
2026-10-0631.2%1,152,5453,690,200
2026-10-0542.0%2,848,5226,781,938
2026-10-0239.2%1,236,2853,153,640
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
-2.0Jan+0.9Feb+2.3Mar-1.6Apr-0.2May+1.0Jun+0.2Jul-1.1Aug+1.4Sep+1.3Oct+2.2Nov+2.8Dec
MonthAvg returnUp yearsYears
Jan−2.0%45%20
Feb+0.9%60%20
Mar+2.3%62%21
Apr−1.6%45%20
May−0.2%35%20
Jun+1.0%60%20
Jul+0.2%45%20
Aug−1.1%65%20
Sep+1.4%65%20
Oct+1.3%45%20
Nov+2.2%70%20
Dec+2.8%70%20
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1445.5
MFI33.2
ADX20.4
Stochastic %K / %D50.8 / 36.1
Williams %R-50.8
CCI-9
TSI / signal-19.7 / -20.1
Chaikin money flow-0.12
ATR$1.77
Bollinger width10.6%
Volume vs 20-day avg1.01x
SupertrendDown

Moving averages and bands

level (price vs level)
SMA 20$60.35 (−1.0%)
SMA 50$62.99 (−5.1%)
SMA 200$58.48 (+2.2%)
EMA 21$60.43 (−1.1%)
EMA 50$61.37 (−2.6%)
EMA 200$58.01 (+3.0%)
Bollinger upper$63.54 (−6.0%)
Bollinger lower$57.16 (+4.5%)
Parabolic SAR$56.27 (+6.2%)
Open the live chart, 110+ indicators

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

https://www.bms.com

Key executives

NameTitlePayBorn
Christopher S. BoernerChief Executive Officer & Chairman$5.8M1971
David V. ElkinsExecutive Vice President & Chief Financial Officer$3.2M1968
Adam LenkowskyExecutive Vice President & Chief Commercialization Officer$3.2M1972
Greg MeyersExecutive Vice President and Chief Digital & Technology Officer$3.0M1973
Karin ShanahanExecutive Vice President, Chief Supply Chain & Operations Officer$2.4M1965
Cristian MassacesiExecutive Vice President, Chief Medical Officer & Head of Development$2.2M1969
Cari GallmanExecutive Vice President, General Counsel & Chief Policy Officer—1980
Charles E. TrianoSVP & Head of Investor Relations——

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
Christopher S. Boerner, Ph.D. Board Chair and Chief Executive Officer2025$1.6M$16.1M$3.8M$21.9M
Samit Hirawat , M.D. Former EVP, Chief Medical Officer, Head of Development2025$964,904$5.8M$928,658$10.3M
Cristian Massacesi , M.D. EVP, Chief Medical Officer, Head of Development2025$388,462$7.9M$660,876$10.1M
Adam Lenkowsky EVP, Chief Commercialization Officer2025$1.1M$6.1M$1.8M$9.3M
David V. Elkins EVP and Chief Financial Officer2025$1.1M$6.0M$1.8M$9.2M
Greg Meyers EVP, Chief Digital and Technology Officer2025$1.1M$4.2M$1.7M$7.2M

Employees

23k201830k201930k202032k202134k202234k202334k202432k2025

Dividends

Ex-dateAmountPaid
2026-10-02$0.632026-11-02
2026-07-02$0.632026-08-03
2026-04-02$0.632026-05-01
2026-01-02$0.632026-02-02
2025-10-03$0.622025-11-03
2025-07-03$0.622025-08-01
2025-04-04$0.622025-05-01
2025-01-03$0.622025-02-03

Moat model

Narrow · Efficient Scale · 2026-06-30
Cost advantage62
Intangibles59
Switching costs55
Network effect33
Efficient scale65
Our component scores (0-100) and overall 55.6; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms